World Journal of Gastroenterology最新文献_第6页

Advances in the research of intestinal fungi in Crohn's disease. 克罗恩病肠道真菌研究进展。

IF 4.3 3区医学

World Journal of Gastroenterology Pub Date : 2024-10-21 DOI: 10.3748/wjg.v30.i39.4318

Mo-Wei Kong, Yang Yu, Peng Wang, Ying Wan, Yu Gao, Chun-Xiang Zhang

{"title":"Advances in the research of intestinal fungi in Crohn's disease.","authors":"Mo-Wei Kong, Yang Yu, Peng Wang, Ying Wan, Yu Gao, Chun-Xiang Zhang","doi":"10.3748/wjg.v30.i39.4318","DOIUrl":"10.3748/wjg.v30.i39.4318","url":null,"abstract":"This article reviews of the original research published by Wu et al in the World Journal of Gastroenterology, delving into the pivotal role of the gut microbiota in the pathogenesis of Crohn's disease (CD). Insights were gained from fecal microbiota transplantation (FMT) in mouse models, revealing the intricate interplay between the gut microbiota, mesenteric adipose tissue (MAT), and creeping fat. The study uncovered the characteristics of inflammation and fibrosis in the MAT and intestinal tissues of patients with CD; moreover, through the FMT mouse model, it observed the impact of samples from healthy patients and those with CD on symptoms. The pathogenesis of CD is complex, and its etiology remains unclear; however, it is widely believed that gut microbiota dysbiosis plays a significant role. Recently, with the development and application of next-generation sequencing technology, research on the role of fungi in the pathogenesis and chronicity of CD has deepened. This editorial serves as a supplement to the research by Wu et al who discussed advances related to the study of fungi in CD.","PeriodicalId":23778,"journal":{"name":"World Journal of Gastroenterology","volume":"30 39","pages":"4318-4323"},"PeriodicalIF":4.3,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11525856/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142568516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current strategies for predicting post-hepatectomy liver failure and a new ultrasound-based nomogram. 目前预测肝切除术后肝功能衰竭的策略和基于超声波的新提名图。

IF 4.3 3区医学

World Journal of Gastroenterology Pub Date : 2024-10-21 DOI: 10.3748/wjg.v30.i39.4254

Xing-Xue Gao, Jun-Feng Li

引用次数: 0

Gut microbiota in gastrointestinal diseases: Insights and therapeutic strategies. 胃肠道疾病中的肠道微生物群：洞察力和治疗策略。

IF 4.3 3区医学

World Journal of Gastroenterology Pub Date : 2024-10-21 DOI: 10.3748/wjg.v30.i39.4329

Lu Jiang, Jian-Gao Fan

{"title":"Gut microbiota in gastrointestinal diseases: Insights and therapeutic strategies.","authors":"Lu Jiang, Jian-Gao Fan","doi":"10.3748/wjg.v30.i39.4329","DOIUrl":"10.3748/wjg.v30.i39.4329","url":null,"abstract":"Considering the bidirectional crosstalk along the gut-liver axis, gut-derived microorganisms and metabolites can be released into the liver, potentially leading to liver injury. In this editorial, we comment on several studies published in the recent issue of the World Journal of Gastroenterology. We focus specifically on the roles of gut microbiota in selected gastrointestinal (GI) diseases that are prevalent, such as inflammatory bowel disease, metabolic dysfunction-associated steatotic liver disease, and hepatitis B virus-related portal hypertension. Over the past few decades, findings from both preclinical and clinical studies have indicated an association between compositional and metabolic changes in the gut microbiota and the pathogenesis of the aforementioned GI disorders. However, studies elucidating the mechanisms underlying the host-microbiota interactions remain limited. The purpose of this editorial is to summarize current findings and provide insights regarding the context-specific roles of gut microbiota. Ultimately, the discovery of microbiome-based biomarkers may facilitate disease diagnosis and the development of personalized medicine.","PeriodicalId":23778,"journal":{"name":"World Journal of Gastroenterology","volume":"30 39","pages":"4329-4332"},"PeriodicalIF":4.3,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11525853/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142568753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Artificial intelligence enhances the management of esophageal squamous cell carcinoma in the precision oncology era. 在精准肿瘤学时代，人工智能加强了对食管鳞状细胞癌的管理。

IF 4.3 3区医学

World Journal of Gastroenterology Pub Date : 2024-10-21 DOI: 10.3748/wjg.v30.i39.4267

Wan-Yue Zhang, Yong-Jian Chang, Rui-Hua Shi

{"title":"Artificial intelligence enhances the management of esophageal squamous cell carcinoma in the precision oncology era.","authors":"Wan-Yue Zhang, Yong-Jian Chang, Rui-Hua Shi","doi":"10.3748/wjg.v30.i39.4267","DOIUrl":"10.3748/wjg.v30.i39.4267","url":null,"abstract":"Esophageal squamous cell carcinoma (ESCC) is the most common histological type of esophageal cancer with a poor prognosis. Early diagnosis and prognosis assessment are crucial for improving the survival rate of ESCC patients. With the advancement of artificial intelligence (AI) technology and the proliferation of medical digital information, AI has demonstrated promising sensitivity and accuracy in assisting precise detection, treatment decision-making, and prognosis assessment of ESCC. It has become a unique opportunity to enhance comprehensive clinical management of ESCC in the era of precision oncology. This review examines how AI is applied to the diagnosis, treatment, and prognosis assessment of ESCC in the era of precision oncology, and analyzes the challenges and potential opportunities that AI faces in clinical translation. Through insights into future prospects, it is hoped that this review will contribute to the real-world application of AI in future clinical settings, ultimately alleviating the disease burden caused by ESCC.","PeriodicalId":23778,"journal":{"name":"World Journal of Gastroenterology","volume":"30 39","pages":"4267-4280"},"PeriodicalIF":4.3,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11525855/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142568526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Novel intervention for alcohol-associated liver disease. 酒精相关肝病的新型干预措施。

IF 4.3 3区医学

World Journal of Gastroenterology Pub Date : 2024-10-21 DOI: 10.3748/wjg.v30.i39.4308

Fei-Qiong Gao, Jia-Qi Zhu, Xu-Dong Feng

引用次数: 0

Modulation of host N6-methyladenosine modification by gut microbiota in colorectal cancer. 肠道微生物群对大肠癌宿主 N6-甲基腺苷修饰的调节作用

IF 4.3 3区医学

World Journal of Gastroenterology Pub Date : 2024-10-14 DOI: 10.3748/wjg.v30.i38.4175

Tian-Qi Jiang, Hao Wang, Wang-XinJun Cheng, Chuan Xie

{"title":"Modulation of host N6-methyladenosine modification by gut microbiota in colorectal cancer.","authors":"Tian-Qi Jiang, Hao Wang, Wang-XinJun Cheng, Chuan Xie","doi":"10.3748/wjg.v30.i38.4175","DOIUrl":"10.3748/wjg.v30.i38.4175","url":null,"abstract":"As a research hotspot in the field of molecular biology, N6-methyladenosine (m6A) modification has made progress in the treatment of colorectal cancer (CRC), leukemia and other cancers. Numerous studies have demonstrated that the tumour microenvironment (TME) regulates the level of m6A modification in the host and activates a series of complex epigenetic signalling pathways through interactions with CRC cells, thus affecting the progression and prognosis of CRC. However, with the diversity in the composition of TME factors, this action is reciprocal and complex. Encouragingly, some studies have experimentally revealed that the intestinal flora can alter CRC cell proliferation by directly acting on m6A and thereby altering CRC cell proliferation. This review summarizes the data, supporting the idea that the intestinal flora can influence host m6A levels through pathways such as methyl donor metabolism and thus affect the progression of CRC. We also review the role of m6A modification in the diagnosis, treatment, and prognostic assessment of CRC and discuss the current status, limitations, and potential clinical value of m6A modification in this field. We propose that additional in-depth research on m6A alterations in CRC patients and their TME-related targeted therapeutic issues will lead to better therapeutic outcomes for CRC patients.","PeriodicalId":23778,"journal":{"name":"World Journal of Gastroenterology","volume":"30 38","pages":"4175-4193"},"PeriodicalIF":4.3,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11525875/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142568120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Endoscopic polidocanol foam sclerobanding for the treatment of Grade II-III internal hemorrhoids: The focus of clinical practice. 内镜下聚氧乙烯醚泡沫硬化剂包扎治疗 II-III 级内痔：临床实践的重点。

IF 4.3 3区医学

World Journal of Gastroenterology Pub Date : 2024-10-14 DOI: 10.3748/wjg.v30.i38.4246

Yu-Yan Zhang, Bing Hu

引用次数: 0

Is Helicobacter pylori infection protective against esophageal cancer? 幽门螺杆菌感染对食道癌有保护作用吗？

IF 4.3 3区医学

World Journal of Gastroenterology Pub Date : 2024-10-14 DOI: 10.3748/wjg.v30.i38.4168

Rick Maity, Arkadeep Dhali, Jyotirmoy Biswas

{"title":"Is Helicobacter pylori infection protective against esophageal cancer?","authors":"Rick Maity, Arkadeep Dhali, Jyotirmoy Biswas","doi":"10.3748/wjg.v30.i38.4168","DOIUrl":"10.3748/wjg.v30.i38.4168","url":null,"abstract":"Helicobacter pylori (H. pylori) infection affects a substantial proportion of the global population and causes various gastric disorders, including gastric cancer. Recent studies have found an inverse relationship between H. pylori infection and esophageal cancer (EC), suggesting a protective role against EC. This editorial focuses on the possible mechanisms underlying the role of H. pylori infection in EC and explores the role of gut microbiota in esophageal carcinogenesis and the practicality of H. pylori eradication. EC has two major subtypes: Esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC), which have different etiologies and risk factors. Gut microbiota can contribute to EC via inflammation-induced carcinogenesis, immunomodulation, lactagenesis, and genotoxin production. H. pylori infection is said to be inversely related to EAC, protecting against EAC by inducing atrophic gastritis, altering serum ghrelin levels, and triggering cancer cell apoptosis. Though H. pylori infection has no significant association with ESCC, COX-2-1195 polymorphisms and endogenous nitrosamine production can impact the risk of ESCC in H. pylori-infected individuals. There are concerns regarding a plausible increase in EC after H. pylori eradication treatments. However, H. pylori eradication is not associated with an increased risk of EC, making it safe from an EC perspective.","PeriodicalId":23778,"journal":{"name":"World Journal of Gastroenterology","volume":"30 38","pages":"4168-4174"},"PeriodicalIF":4.3,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11525877/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142568082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Physician-dependent diagnosis delay in Crohn's disease: A pseudo-proposition or not? 依赖医生的克罗恩病诊断延迟：伪命题还是假命题？

IF 4.3 3区医学

World Journal of Gastroenterology Pub Date : 2024-10-14 DOI: 10.3748/wjg.v30.i38.4242

Yan Zeng, Jun-Wen Zhang, Jian Yang

{"title":"Physician-dependent diagnosis delay in Crohn's disease: A pseudo-proposition or not?","authors":"Yan Zeng, Jun-Wen Zhang, Jian Yang","doi":"10.3748/wjg.v30.i38.4242","DOIUrl":"10.3748/wjg.v30.i38.4242","url":null,"abstract":"The challenge of diagnosis delay in inflammatory bowel disease (IBD) has emerged as a significant concern for both patients and healthcare professionals. The widely accepted notion that there is an extended time frame from the onset of symptoms to the definitive diagnosis is often attributed to the heterogeneity of IBD and the non-specificity of clinical manifestations. Specific to patients with Crohn's disease, the issue of delayed diagnosis appears to be more pronounced across different regions globally. The intricate interplay of real-world factors has led to debates regarding the primary contributors to these diagnostic delays. Drawing a comparison solely between patients and physicians and implicating the latter as the predominant influence factor may fall into a simplistic either-or logical trap that may obscure the truth. This letter, grounded in published evidence, explores areas for improvement in a forthcoming paper within the field, hoping to pinpoint the culprit behind the diagnosis delay issue for IBD patients rather than simply attributing it to so-called \"physician-dependent factors\". Our objective is to motivate healthcare providers and policymakers in relevant fields to reflect on strategies for addressing this problem to reduce diagnostic delays and enhance patient outcomes.","PeriodicalId":23778,"journal":{"name":"World Journal of Gastroenterology","volume":"30 38","pages":"4242-4245"},"PeriodicalIF":4.3,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11525879/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142568167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Survival outcomes in early-onset oesophageal adenocarcinoma patients: A systematic review and meta-analyses. 早期食管腺癌患者的生存预后：系统回顾和荟萃分析。

IF 5.4 3区医学

World Journal of Gastroenterology Pub Date : 2024-10-14 DOI: 10.3748/wjg.v30.i38.4221

Ashleigh Russell, Shauna Mitchell, Richard C Turkington, Helen G Coleman

{"title":"Survival outcomes in early-onset oesophageal adenocarcinoma patients: A systematic review and meta-analyses.","authors":"Ashleigh Russell, Shauna Mitchell, Richard C Turkington, Helen G Coleman","doi":"10.3748/wjg.v30.i38.4221","DOIUrl":"10.3748/wjg.v30.i38.4221","url":null,"abstract":"Background: The incidence of oesophageal adenocarcinoma (OAC) has been reported to be increasing in many countries. Alongside this trend, an increase in incidence of early-onset OAC, defined as OAC in adults aged under 50 years, has been observed. It is unclear whether survival outcomes for early-onset OAC patients differ from older age groups.Aim: To investigate survival outcomes in early-onset OAC patients.Methods: Ovid Medline and Embase were searched from inception to January 2022 for relevant studies relating to early-onset OAC and survival outcomes. Results regarding the overall five-year survival and risk of death of younger and older patients with OAC were extracted and pooled using meta-analyses to produce pooled estimates and 95%CIs where possible.Results: Eleven studies which compared survival of early-onset OAC, defined as age at diagnosis of < 50 years, with older patients were included. A narrative review of median and mean survival demonstrated conflicting results, with studies showing early-onset OAC patients having both better and worse outcomes compared to older age groups. A meta-analysis of five-year survival demonstrated similar outcomes across age groups, with 22%-25% of patients in the young, middle and older age groups alive after five years. A meta-analysis of four studies demonstrated that early-onset OAC patients did not have a significantly increased risk of death compared to middle-aged patients (hazard ratio 1.12, 95%CI: 0.85-1.47).Conclusion: Results suggest that early-onset OAC patients do not have a significantly different survival compared to older patients, but further population-based research, taking into account stage and treatment, is required.","PeriodicalId":23778,"journal":{"name":"World Journal of Gastroenterology","volume":"30 38","pages":"4221-4231"},"PeriodicalIF":5.4,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11525870/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142568419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0